Daneng Li, MD

Articles

EMERALD-1 Study Results

October 25th 2024

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Discussion and Summary

October 25th 2024

Panelists discuss the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.

LEAP-012 Study Results

October 25th 2024

Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.

Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

October 25th 2024

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Use of monotherapy (IO or TKI) or localized treatment in First Line

October 18th 2024

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

Current Treatment in First Line – IO + TKI or IO + IO

October 18th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Treatment Decisions Based on BLCL Stage

October 7th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

October 7th 2024

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.

Dr Li on the Utility of ADG126 Plus Pembrolizumab in MSS CRC

March 29th 2024

Daneng Li, MD, discusses the implications of a study evaluating ADG126 in combination with pembrolizumab in patients with MSS colorectal cancer.

Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC

January 20th 2024

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

Dr Li on Frontline Treatment Considerations With IO-Based Combinations in Unresectable HCC

November 15th 2023

Daneng Li, MD, discusses considerations when choosing between treatment with immuno-oncology-based combination regimens or single-agent TKIs in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma, highlighting which patient and disease factors influence these decisions.

Dr. Li on the Potential For First-Line Triplet Therapy in HCC

September 8th 2023

Daneng Li, MD, discusses the investigation of triplet combination therapy for patients with hepatocellular carcinoma in the phase 1/2 Morpheus-Liver study.

Dr Li on the Impact of Immune-Related Adverse Effects in HCC

September 6th 2023

Daneng Li, MD, discusses how immune-related adverse effects can affect the treatment of patients with gastrointestinal cancer, specifically those with unresectable hepatocellular carcinoma.

Dr Li on the Evolution of HER2-Targeted Therapy in HER2+ CRC

September 5th 2023

Daneng Li, MD, discusses the evolution of treating patients with HER2-positive colorectal cancer and highlights the effects of implementing HER2-targeted therapy in this patient population.

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

April 10th 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Management of Child-Pugh B Patients with Advanced HCC

April 3rd 2023

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

Treatment Considerations for Advanced HCC in Second Line and Beyond

April 3rd 2023

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

March 27th 2023

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

March 27th 2023

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

March 20th 2023

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.